Long-term Hodgkin Lymphoma Survivors: A Glimpse of What Happens 10 Years After Treatment

2020 ◽  
Vol 20 (8) ◽  
pp. e506-e512 ◽  
Author(s):  
Filomena Emanuela Laddaga ◽  
Marco Moschetta ◽  
Tommasina Perrone ◽  
Sebastio Perrini ◽  
Paolo Colonna ◽  
...  
2021 ◽  
pp. 1-9
Author(s):  
Matthew R. LeBlanc ◽  
Sheryl Zimmerman ◽  
Thomas W. LeBlanc ◽  
Ashley Leak Bryant ◽  
Kathryn E. Hudson ◽  
...  

2018 ◽  
Vol 185 (2) ◽  
pp. 377-380 ◽  
Author(s):  
Amie E. Hwang ◽  
Vickie Marshall ◽  
David V. Conti ◽  
Bharat N. Nathwani ◽  
Thomas M. Mack ◽  
...  

2016 ◽  
Vol 25 (3) ◽  
pp. 739-748 ◽  
Author(s):  
Shah-Jalal Sarker ◽  
Sophia K. Smith ◽  
Kashfia Chowdhury ◽  
Patricia A. Ganz ◽  
Sheryl Zimmerman ◽  
...  

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 19537-19537
Author(s):  
I. Cedrych ◽  
A. Polakiewicz-Gilowska ◽  
E. Nowara ◽  
A. Deptala

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e20592-e20592
Author(s):  
Benjamin Reed Griffin ◽  
Carrie A. Thompson ◽  
Thomas Matthew Habermann ◽  
Thomas E. Witzig ◽  
Kay Ristow ◽  
...  

2016 ◽  
Vol 34 (3_suppl) ◽  
pp. 107-107
Author(s):  
Erin Elizabeth Hahn ◽  
Yi-Lin Wu ◽  
Jazmine Garcia Delgadillo ◽  
Corrine E. Munoz-Plaza

107 Background: Adolescent and young adult (AYA) Hodgkin lymphoma survivors are at high risk for long-term and late effects. Post-treatment guidelines are available from the National Comprehensive Cancer Network (NCCN) and others; however, adherence to these guidelines is unknown. The purpose of this study was to identify AYA Hodgkin survivors from an integrated health care system and examine use of post-treatment services. Methods: We identified patients diagnosed between 2000 and 2010, ages 15 to 39. We identified use of NCCN recommended services (oncology visits, labs, CT) and non-recommended services (PET scan, CT after first year). Multivariate logistic regression was used to identify associations between receipt of recommended services within first 12 months post-treatment (oncology visits, labs, CT) and patient (gender, race/ethnicity) and cancer characteristics (stage, diagnosis age, diagnosis year). Results: We identified 354 patients (see table). Almost all had recommended oncology visits within the first 5 years (96%); 70% received recommended labs. Two-thirds received a recommended CT scan within 12 months post- treatment. However, 47% received a non-recommended CT in year 2 and 35% in year 3, and 33% received a non-recommended PETs. Overall, 48% received all recommended care within the first 12 months. Diagnosis year was significant in regression, with those diagnosed 2000-2005 less likely to receive recommended care than those diagnosed 2006-2010 (OR = 0.007, p < .0001). Conclusions: Less than half of patients received recommended care within the first year post-treatment. These results will inform development of effective programs to meet survivors’ needs. Next steps include exploring risk-stratified patterns of care in long-term survivors. [Table: see text]


2011 ◽  
Vol 91 (2) ◽  
pp. 215-221 ◽  
Author(s):  
Irit Avivi ◽  
Emilia Hardak ◽  
Beatrice Shaham ◽  
Mordechai Igla ◽  
Jacob M. Rowe ◽  
...  

2017 ◽  
Vol 35 ◽  
pp. 313-313
Author(s):  
S. Viviani ◽  
M. Soldarini ◽  
N. Cieri ◽  
I. Arendar ◽  
C. Materazzo ◽  
...  

Cancer ◽  
2007 ◽  
Vol 109 (8) ◽  
pp. 1659-1667 ◽  
Author(s):  
Floortje Mols ◽  
Neil K. Aaronson ◽  
Ad J. J. M. Vingerhoets ◽  
Jan-Willem W. Coebergh ◽  
Gerard Vreugdenhil ◽  
...  

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4700-4700
Author(s):  
Thomas M. Habermann ◽  
Brett A. Bauer ◽  
Carol A. Janney ◽  
Teresa A. Rummans ◽  
Jeff A. Sloan ◽  
...  

Abstract Patients during cancer treatment and cancer survivors frequently utilize complementary and alternative medicine (CAM) therapies. While the beliefs and knowledge regarding CAM of many cancer-specific patient groups have been well studied such as breast cancer patients and prostate cancer patients, no specific evaluation of lymphoma survivors and their beliefs and knowledge about CAM has been undertaken. Because CAM can yield both risks such as toxicity and displacement of efficacious therapy as well as potential benefits such as improvement in quality of life and mood, we surveyed lymphoma survivors in a pilot study to ascertain their current beliefs, knowledge, and utilization of CAM. Using the Mayo Tumor Registry, we identified eligible patients who were 16 years or older at diagnosis, U.S. residents, first diagnosed with Hodgkin or non-Hodgkin lymphoma from 1984–1998, diagnosed and/or initially treated at Mayo Clinic Rochester, and survived for 5 to 20 years (N=2,485). In October of 2004, we mailed a 23-page survey to 95 randomly selected patients; 7 were found to be ineligible (deceased or too ill). Of the 88 remaining patients, we were able to find a correct address for 82, and 57 completed a survey for a 70% participation rate. Complete data were available on 54 patients at the time of this analysis. The mean age at completion of the questionnaire was 60.8 years (26.1–86.7). The mean time since diagnosis was 12.0 years (6.3–19.9), and 52% survived more than 11 years. The histologies included 22 (39%) Hodgkin lymphoma, 21 (38%) diffuse large B-cell, 3 (5%) follicular, 1 (1%) high grade, 5 (9%) peripheral T-cell lymphoma, and 4 (7%) other. A majority of patients expressed no knowledge about the use of CAM cancer care, while only 4% of patients responded that CAM could both cure cancer and that it was perfectly safe. Ten to twenty percent of patients felt that CAM could assist other therapeutic interventions, relieve symptoms, assist the body to heal or increase quality of life. Fifteen percent of patients reported that CAM utilization increased the feeling of control, and 24% reported that CAM could have side effects. With respect to CAM utilization, overall 32% of patients had ever used CAM, but no patients reported that CAM usage was directed specifically towards their lymphoma. The most commonly used CAM modalities were chiropractic (39%), massage (21%), relaxation therapy (7%), meditation (5%) and acupuncture (5%). Overall usage of dietary supplements was relatively low, with green tea, garlic, flax seed, and echinacea being the only dietary supplements used by more than 10% of respondents. Five percent had used St. John’s Wort and 7% had used shark cartilage. In conclusion, lymphoma long-term survivors appear to use CAM at a rate similar to the general population, which does not follow the typical pattern seen in other cancer survivorship populations. The use of St. John’s Wort has potential risks if not identified prospectively. At the same time, lack of access to potentially beneficial modalities was also identified, and these observations suggest the opportunity for further study of targeted educational interventions regarding the use of CAM in this population.


Sign in / Sign up

Export Citation Format

Share Document